Literature DB >> 23720066

Adult primitive neuroectodermal tumors: the prognostic value of supratentorial location.

Rikesh Gandhi1, Ranjith Babu, Thomas J Cummings, Cory Adamson.   

Abstract

Primitive neuroectodermal tumors (PNETs) are tumors which primarily consist of undifferentiated round neuroepithelial cells. Central nervous system PNETs can be divided into two genetically distinct groups: infratentorial PNET (iPNET)/medulloblastoma and supratentorial PNET (sPNET). Currently, the comparative outcome of adult patients with sPNETs and iPNETs is unknown. In this study we have utilized the Surveillance, Epidemiology, and End Results database to perform a comparative analysis of 103 cases of adult sPNET and 669 adult medulloblastoma cases. Additionally we have analyzed various factors to identify their prognostic significance and characterize the optimal treatment for these tumors. Patients with sPNETs were seen to have a significantly worse survival than those diagnosed with medulloblastomas (16 vs. 155 months, p < 0.0001). Elderly patients (15 vs. 114 months, p < 0.0001) and those over the age of 40 (68 vs. 147 months, p < 0.0001) experienced significantly worse survival than younger patients. In contrast, radiotherapy (143 vs. 26 months, p < 0.0001), surgical resection (116 vs. 22 months, p = 0.0010) and the extent of resection (EOR) (173 vs. 81 months, p = 0.0005) resulted in significantly improved patient survival. Multivariate analysis revealed age greater than 40 years (HR: 1.57; 95 % CI: 1.17-2.11; p = 0.0028) and sPNET pathology (HR: 3.41; 95 % CI: 2.47-4.72; p < 0.0001) to be poor prognostic factors for survival while radiotherapy (HR: 0.52; 95 % CI: 0.38-0.71; p < 0.0001) and the EOR (HR: 0.73; 95 % CI: 0.55-0.96; p = 0.023) were associated with significantly improved survival. The treatment of sPNETs should therefore include maximal surgical resection when feasible followed by radiotherapy as these treatments have been demonstrated to confer a survival benefit. Additional studies are needed to identify effective chemotherapeutics and specific treatment regimens for adults with sPNETs.

Entities:  

Mesh:

Year:  2013        PMID: 23720066     DOI: 10.1007/s11060-013-1163-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  Cerebral primitive neuroectodermal tumor in an adult, with spinal cord metastasis after 18-year dormancy.

Authors:  D N Louis; F H Hochberg
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

2.  Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization.

Authors:  D A Reardon; E Michalkiewicz; J M Boyett; J E Sublett; R E Entrekin; S T Ragsdale; M B Valentine; F G Behm; H Li; R L Heideman; L E Kun; D N Shapiro; A T Look
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

3.  Primitive supratentorial neuroectodermal tumor in an adult.

Authors:  A T Kouyialis; E I Boviatsis; I K Karampelas; S Korfias; P Korkolopoulou; D E Sakas
Journal:  J Clin Neurosci       Date:  2005-05       Impact factor: 1.961

4.  Computed tomography and magnetic resonance imaging findings in primitive neuroectodermal tumours in adults.

Authors:  D Pickuth; U Leutloff
Journal:  Br J Radiol       Date:  1996-01       Impact factor: 3.039

5.  Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors.

Authors:  C Russo; M Pellarin; O Tingby; A W Bollen; K R Lamborn; G Mohapatra; V P Collins; B G Feuerstein
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

6.  Supratentorial primitive neuroectodermal tumors of the central nervous system in adults: molecular and histopathologic analysis of 12 cases.

Authors:  Marco Gessi; Prashanth Setty; Michele Bisceglia; Anja zur Muehlen; Libero Lauriola; Andreas Waha; Felice Giangaspero; Torsten Pietsch
Journal:  Am J Surg Pathol       Date:  2011-04       Impact factor: 6.394

7.  Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome.

Authors:  E H Baldini; G D Demetri; C D Fletcher; J Foran; K C Marcus; S Singer
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

8.  Validity of cancer registry data for measuring the quality of breast cancer care.

Authors:  Jennifer L Malin; Katherine L Kahn; John Adams; Lorna Kwan; Marianne Laouri; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

Review 9.  Primitive neuroectodermal tumour in a 60-year-old man: a case report and literature review.

Authors:  M J Balafouta; J R Kouvaris; A C Miliadou; X N Papacharalampous; D V Kolokouris; V E Kouloulias; A D Mariolis; L J Vlahos
Journal:  Br J Radiol       Date:  2003-01       Impact factor: 3.039

10.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

Authors:  B K Rasheed; T T Stenzel; R E McLendon; R Parsons; A H Friedman; H S Friedman; D D Bigner; S H Bigner
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

View more
  4 in total

1.  Patterns of care in adult medulloblastoma: results of an international online survey.

Authors:  Rasha Cosman; Christopher S B Brown; Kevin C DeBraganca; Mustafa Khasraw
Journal:  J Neurooncol       Date:  2014-07-16       Impact factor: 4.130

2.  Tumor Location and Treatment Modality are Associated with Overall Survival in Adult Medulloblastoma.

Authors:  Anthony K Ma; Isaac Freedman; Jun Hui Lee; Danielle Miyagishima; Osama Ahmed; Jacky Yeung
Journal:  Cureus       Date:  2020-02-20

3.  Outcomes of adult medulloblastoma treated with a multimodality approach: A tertiary cancer center experience.

Authors:  Supriya Mallick; Ajeet Kumar Gandhi; Rony Benson; Daya Nand Sharma; Kunhi Parambath Haresh; Subhash Gupta; Pramod Kumar Julka; Goura Kisor Rath
Journal:  South Asian J Cancer       Date:  2015 Oct-Dec

4.  Treatment Outcome and Prognostic Molecular Markers of Supratentorial Primitive Neuroectodermal Tumors.

Authors:  Seo Hee Choi; Se Hoon Kim; Kyu-Won Shim; Jung Woo Han; Junjeong Choi; Dong-Seok Kim; Chuhl Joo Lyu; Jun Won Kim; Chang-Ok Suh; Jaeho Cho
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.